SDS-Page
(>90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).)
COVID 19 Spike protein, Alpha Variant of Concern, B.1.1.7 variant Coronavirus Recombinant Protein
Recombinant SARS-CoV-2 Spike protein, Alpha Variant of Concern, B.1.1.7 variant (United Kingdom, HV69-70del, Y144del, N501Y, A570D, D614G, P681H, T716I, S982A and D1118H)
Applications
Western Blot
Purity
Affinity chromatography. >95%
Synonyms
COVID 19 Spike protein; Alpha Variant of Concern; B.1.1.7 variant Coronavirus; Recombinant SARS-CoV-2 Spike protein; B.1.1.7 variant (United Kingdom; HV69-70del; Y144del; N501Y; A570D; D614G; P681H; T716I; S982A and D1118H); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; B.1.1.7 Variant of Concern; UK mutant; United Kingdom; S982A; D1118H; B.1.1.7 variant Coronavirus recombinant protein
Host
HEK293 Cells
Purity/Purification
Affinity chromatography. >95%
Form/Format
Liquid
Sequence Positions
16-1211
Sequence
VNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLGVYKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIDDTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNSYECDIPIGAGICASYQTQTNSHRGAGSVASQSIIAYTMSLGAENSVAYSNNSIAIPINFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGPALQIPFAMQMAYRFNGIGVTQVLYENQKLIANQFNSAIGKIQDSLSSTPSALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILARLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTHNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDIGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKGSGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHH
Applicable Applications for COVID 19 Spike protein, Alpha Variant of Concern, B.1.1.7 variant Coronavirus recombinant protein
Western Blot (WB), Immunoassay (IA), Functional Studies
Endotoxin
Less than 0.1 ng/ug (1 IEU/ug), as measured by LAL method.
Tag Information
8xHis at the C-terminus
Buffer
PBS 20% Glycerol
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
SDS-Page
(>90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).)
SDS-Page
(>90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).)
Related Product Information for COVID 19 Spike protein, Alpha Variant of Concern, B.1.1.7 variant Coronavirus recombinant protein
Full-length soluble with foldon trimerization motif, mutated Furin recognition site and 4 stabilising mutations (A892P, A942P, K986P and V987P), based on/modified from Amanat et al, 2020 and Hsieh et al, 2020.
The first reports of atypical pneumonia in China were announced at the very end of 2019, in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel ?-CoV (1), named SARS-CoV-2, which started spreading very quickly causing a global pandemic COVID-19. Spike protein attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2, 3). The protein forms a trimer in vivo mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer’s group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6). The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G (7). The B.1.1.7 variant is a strain of the coronavirus with 8 distinctive mutations (in addition to the D614G) in the virus's spike protein and was first identified in autumn 2020 as the result of genetic sequencing of positive covid-19 samples by the Covid-19 Genomics UK Consortium (8).
The first reports of atypical pneumonia in China were announced at the very end of 2019, in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel ?-CoV (1), named SARS-CoV-2, which started spreading very quickly causing a global pandemic COVID-19. Spike protein attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2, 3). The protein forms a trimer in vivo mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer’s group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6). The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G (7). The B.1.1.7 variant is a strain of the coronavirus with 8 distinctive mutations (in addition to the D614G) in the virus's spike protein and was first identified in autumn 2020 as the result of genetic sequencing of positive covid-19 samples by the Covid-19 Genomics UK Consortium (8).
References
1. Zhu N., Zhang D., Wang W., et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med., 2020;382:727–733.
2. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020;181(2):271-280.
3. Wrapp D., Wang N., Corbett KS., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020;367(6483):1260-1263.
4. Yin HS., Wen X., Paterson RG., Lamb RA., Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature, 2006;439(7072):38-44.
5. Amanat, F., Stadlbauer, D., Strohmeier, S., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med., 2020;26:1033–1036.
6. Stadlbauer, D., Amanat, F., Chromikova, V., et al. SARS?CoV?2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology, 2020;57, e100.
7. Korber, B., Fischer, W., Gnanakaran, S., et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020;182:1-16.
8. Tegally, H., Wilkinson, E., Giovanetti, M., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple Spike mutations in South Africa. MedRxiv, 21.12.2020;182:1-16.
2. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020;181(2):271-280.
3. Wrapp D., Wang N., Corbett KS., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020;367(6483):1260-1263.
4. Yin HS., Wen X., Paterson RG., Lamb RA., Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature, 2006;439(7072):38-44.
5. Amanat, F., Stadlbauer, D., Strohmeier, S., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med., 2020;26:1033–1036.
6. Stadlbauer, D., Amanat, F., Chromikova, V., et al. SARS?CoV?2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology, 2020;57, e100.
7. Korber, B., Fischer, W., Gnanakaran, S., et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020;182:1-16.
8. Tegally, H., Wilkinson, E., Giovanetti, M., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple Spike mutations in South Africa. MedRxiv, 21.12.2020;182:1-16.
NCBI and Uniprot Product Information
UniProt Accession #
Molecular Weight
Estimated Molecular Weight: ~190 kDa
Similar Products
Product Notes
The COVID 19 Spike protein, Alpha Variant of Concern, B.1.1.7 variant Coronavirus (Catalog #AAA184025) is a Recombinant Protein produced from HEK293 Cells and is intended for research purposes only. The product is available for immediate purchase. The immunogen sequence is 16-1211 with tag 8xHis at the C-terminus!!!!Buffer||PBS 20% Glycerol!!Dry Ice Shipment||Extra charge fee may add to your shipping cost as dry ice is required to ship this product. AAA Biotech's COVID 19 Spike protein, Alpha Variant of Concern, B.1.1.7 variant Coronavirus can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Immunoassay (IA), Functional Studies . Researchers should empirically determine the suitability of the COVID 19 Spike protein, Alpha Variant of Concern, B.1.1.7 variant Coronavirus for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. The amino acid sequence is listed below: VNLTTRTQLP PAYTNSFTRG VYYPDKVFRS SVLHSTQDLF LPFFSNVTWF HAISGTNGTK RFDNPVLPFN DGVYFASTEK SNIIRGWIFG TTLDSKTQSL LIVNNATNVV IKVCEFQFCN DPFLGVYKNN KSWMESEFRV YSSANNCTFE YVSQPFLMDL EGKQGNFKNL REFVFKNIDG YFKIYSKHTP INLVRDLPQG FSALEPLVDL PIGINITRFQ TLLALHRSYL TPGDSSSGWT AGAAAYYVGY LQPRFLLKYN ENGTITDAVD CALDPLSETK CTLKSFTVEK GIYQTSNFRV QPTESIVRFP NITNLCPFGE VFNATRFASV YAWNRKRISN CVADYSVLYN SASFSTFKCY GVSPTKLNDL CFTNVYADSF VRGDEVRQIA PGQTGKIADY NYKLPDDFTG CVIAWNSNNL DSKVGGNYNY LYRLFRKSNL KPFERDISTE IYQAGSTPCN GVEGFNCYFP LQSYGFQPTY GVGYQPYRVV VLSFELLHAP ATVCGPKKTN LVKNKCVNFN FNGLTGTGVL TESNKKFLPF QQFGRDIDDT TDAVRDPQTL EILDITPCSF GGVSVITPGT NTSNQVAVLY QGVNCTEVPV AIHADQLTPT WRVYSTGSNV FQTRAGCLIG AEHVNSYECD IPIGAGICAS YQTQTNSHRG AGSVASQSII AYTMSLGAEN SVAYSNNSIA IPINFTISVT TEILPVSMTK TSVDCTMYIC GDSTECSNLL LQYGSFCTQL NRALTGIAVE QDKNTQEVFA QVQIYKTPPI KDFGGFNFSQ ILPDPSKPSK RSFIEDLLFN KVTLADAGFI KQYGDCLGDI AARDLICAQK FNGLTVLPPL LTDEMIAQYT SALLAGTITS GWTFGAGPAL QIPFAMQMAY RFNGIGVTQV LYENQKLIAN QFNSAIGKIQ DSLSSTPSAL GKLQDVVNQN AQALNTLVKQ LSSNFGAISS VLNDILARLD PPEAEVQIDR LITGRLQSLQ TYVTQQLIRA AEIRASANLA ATKMSECVLG QSKRVDCGKG YHLMSFPQSA PHGVVFLHVT YVPAQEKNFT TAPAICHDGK AHFPREGVFV SNGTHWFVTQ RNFYEPQIIT THNTFVSGNC DVVIGIVNNT VYDPLQPELD SFKEELDKYF KNHTSPDVDL GDIGINASVV NIQKEIDRLN EVAKNLNESL IDLQELGKYE QYIKGSGSGY IPEAPRDGQA YVRKDGEWVL LSTFLGSGHH HHHHHH. It is sometimes possible for the material contained within the vial of "COVID 19 Spike protein, Alpha Variant of Concern, B.1.1.7 variant Coronavirus, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
